The IFN-γ ELISPOT assay showed many more immunospots after PD-1–laIL-2 treatment (Figure 4H), which indicates that PD-1–laIL-2 directly increases the tumor-specific T cell response. The gene discussed is IFNG; the disease is neoplasm.